Rivastigmine for the treatment of dementia associated with Parkinson&rsquo;s disease

Código QR

Rivastigmine for the treatment of dementia associated with Parkinson&rsquo;s disease

Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USAAbstract: Parkinson&rsquo;s disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jennifer L Reingold, John C Morgan, Kapil D Sethi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b56e2e1c4a454f91ba66d014314d612c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer&rsquo;s disease in daily practice
por: Seibert J, et al.
Publicado: (2012)

Rivastigmine in Chinese patients with subcortical vascular dementia
por: Vincent Mok, et al.
Publicado: (2007)

Rasagiline in treatment of Parkinson&rsquo;s disease
por: Lakshmi Nayak, et al.
Publicado: (2008)

Current approaches to the treatment of Parkinson&rsquo;s disease
por: Joseph Jankovic, et al.
Publicado: (2008)

Update on ropinirole in the treatment of Parkinson&rsquo;s disease
por: Holly A Shill, et al.
Publicado: (2008)

Update on the use of pramipexole in the treatment of Parkinson&rsquo;s disease
por: Radu Constantinescu
Publicado: (2008)

Two cases of Alzheimer&#39;s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
por: Kimura T, et al.
Publicado: (2012)

Potential cellular and regenerative approaches for the treatment of Parkinson&rsquo;s disease
por: Emma L Lane, et al.
Publicado: (2008)

Sleep disorders in Parkinson&rsquo;s disease
por: Israt Jahan, et al.
Publicado: (2009)

Depression in Parkinson&rsquo;s disease: Health risks, etiology, and treatment options
por: Pasquale G Frisina, et al.
Publicado: (2008)

Ceruloplasmin and iron in Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease: a synopsis of recent studies
por: Kristinsson J, et al.
Publicado: (2012)

Parkinson&rsquo;s disease and the frequent reasons for emergency admission
por: Ozlem Guneysel, et al.
Publicado: (2008)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson&rsquo;s disease: implications for patients
por: Antonini A, et al.
Publicado: (2011)

Psychiatric disorders in primary focal dystonia and in Parkinson&rsquo;s disease
por: Fernando MV Dias, et al.
Publicado: (2011)

Could lysine supplementation prevent Alzheimer&rsquo;s dementia? A novel hypothesis
por: Robert N Rubey
Publicado: (2010)

Daytime sleepiness in elderly Parkinson&rsquo;s disease patients and treatment with the psychostimulant modafinil: A preliminary study
por: Johan L&ouml;kk
Publicado: (2010)

Parkinson&rsquo;s disease patients&rsquo; subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life
por: Skogar &Ouml;, et al.
Publicado: (2012)

Beneficial effect of pramipexole for motor function and depression in Parkinson&rsquo;s disease
por: Osamu Kano, et al.
Publicado: (2009)

A randomized controlled trial of quetiapine for psychosis in Parkinson&rsquo;s disease
por: Paul Shotbolt, et al.
Publicado: (2009)

Depressive symptoms in Parkinson&rsquo;s disease and in non-neurological medical illnesses
por: Assogna F, et al.
Publicado: (2013)

Did depressive symptoms affect recognition of emotional prosody in Parkinson&rsquo;s disease?
por: Adriana V&eacute;lez Feij&oacute;, et al.
Publicado: (2008)

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson&rsquo;s disease (PD): relevance for motor and non-motor features
por: Angelo Antonini, et al.
Publicado: (2008)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas P, et al.
Publicado: (2013)

Aripiprazole in the treatment of Huntington&rsquo;s disease: a case series
por: Andrea Ciammola, et al.
Publicado: (2008)

The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na+,&nbsp;K+)-, Mg2+-ATPase activities, antioxidant status, and learning performance of aged rats
por: Haris Carageorgiou, et al.
Publicado: (2008)

Optimizing levodopa therapy for Parkinson&rsquo;s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: David J Brooks
Publicado: (2008)

Parkinson’s disease-associated melanin steal
por: Hinz M, et al.
Publicado: (2014)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
por: Kano O, et al.
Publicado: (2013)

An update on the toxicity of A&beta; in Alzheimer&rsquo;s disease
por: J&uuml;rgen G&ouml;tz, et al.
Publicado: (2008)

Editor&rsquo;s choice: the best of 2011&ndash;2012
por: Pinder RM
Publicado: (2013)

Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
por: Fereshtehnejad SM, et al.
Publicado: (2013)

Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China
por: Zou YM, et al.
Publicado: (2015)

Prevalence of Parkinson’s disease and other types of Parkinsonism in Al Kharga district, Egypt
por: El-Tallawy HN, et al.
Publicado: (2013)

Review: management of Parkinson&#39;s disease
por: Pedrosa DJ, et al.
Publicado: (2013)

Brain amyloid &beta; protein and memory disruption in Alzheimer&rsquo;s disease
por: Weiming Xia
Publicado: (2010)

Update on the use of memantine in Alzheimer&rsquo;s disease
por: Robert J van Marum
Publicado: (2009)

Social phobia in Parkinson’s disease: Prevalence and risk factors
por: Gultekin BK, et al.
Publicado: (2014)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer&rsquo;s disease
por: Umamon Puangthong, et al.
Publicado: (2009)

Neuro-Beh&ccedil;et&rsquo;s disease: A report of sixteen patients
por: Radi Shahien, et al.
Publicado: (2010)

Do physical exercise and reading reduce the risk of Parkinson’s disease? a cross-sectional study on factors associated with Parkinson’s disease in elderly Chinese veterans
por: Zou YM, et al.
Publicado: (2015)